Daniel E Falk

List of Publications by Year
in descending order

37 papers	2,167 citations	257450 24 h-index	345221 36 g-index
37 all docs	37 docs citations	37 times ranked	1995 citing authors

#	Article	IF	Citations
1	Heterogeneity of Alcohol Use Disorder: Understanding Mechanisms to Advance Personalized Treatment. Alcoholism: Clinical and Experimental Research, 2015, 39, 579-584.	2.4	233
2	A Double-Blind, Placebo-Controlled Trial Assessing the Efficacy of Varenicline Tartrate for Alcohol Dependence. Journal of Addiction Medicine, 2013, 7, 277-286.	2.6	220
3	Medications development to treat alcohol dependence: a vision for the next decade. Addiction Biology, 2012, 17, 513-527.	2.6	176
4	Percentage of Subjects With No Heavy Drinking Days: Evaluation as an Efficacy Endpoint for AlcoholClinical Trials. Alcoholism: Clinical and Experimental Research, 2010, 34, 2022-2034.	2.4	156
5	Clinical Validation of Reduced Alcohol Consumption After Treatment for Alcohol Dependence Using the World Health Organization Risk Drinking Levels. Alcoholism: Clinical and Experimental Research, 2017, 41, 179-186.	2.4	123
6	Change in non-abstinent WHO drinking risk levels and alcohol dependence: a 3 year follow-up study in the US general population. Lancet Psychiatry,the, 2017, 4, 469-476.	7.4	108
7	A Doubleâ€Blind, Placeboâ€Controlled Trial to Assess the Efficacy of Quetiapine Fumarate XR in Very Heavyâ€Drinking Alcoholâ€Dependent Patients. Alcoholism: Clinical and Experimental Research, 2012, 36, 406-416.	2.4	85
8	Drinking Risk Level Reductions Associated with Improvements in Physical Health and Quality of Life Among Individuals with Alcohol Use Disorder. Alcoholism: Clinical and Experimental Research, 2018, 42, 2453-2465.	2.4	82
9	Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials. JAMA Psychiatry, 2019, 76, 374.	11.0	77
10	Potential medications for the treatment of alcohol use disorder: An evaluation of clinical efficacy and safety. Substance Abuse, 2016, 37, 286-298.	2.3	75
11	A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence. Neuropsychopharmacology, 2017, 42, 1012-1023.	5.4	61
12	Gabapentin Enacarbil Extendedâ€Release for Alcohol Use Disorder: A Randomized, Doubleâ€Blind, Placeboâ€Controlled, Multisite Trial Assessing Efficacy and Safety. Alcoholism: Clinical and Experimental Research, 2019, 43, 158-169.	2.4	60
13	Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications Development. Alcoholism: Clinical and Experimental Research, 2016, 40, 1368-1379.	2.4	55
14	Moderators of Varenicline Treatment Effects in a Double-Blind, Placebo-Controlled Trial for Alcohol Dependence. Journal of Addiction Medicine, 2015, 9, 296-303.	2.6	50
15	Measures of outcome for stimulant trials: ACTTION recommendations and research agenda. Drug and Alcohol Dependence, 2016, 158, 1-7.	3.2	49
16	Methods to Analyze Treatment Effects in the Presence of Missing Data for a Continuous Heavy Drinking Outcome Measure When Participants Drop Out from Treatment in Alcohol Clinical Trials. Alcoholism: Clinical and Experimental Research, 2014, 38, 2826-2834.	2.4	48
17	Posttreatment Lowâ€Risk Drinking as a Predictor of Future Drinking and Problem Outcomes Among Individuals with Alcohol Use Disorders. Alcoholism: Clinical and Experimental Research, 2013, 37, E373-80.	2.4	44
18	World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom. Addiction, 2020, 115, 1668-1680.	3.3	44

#	Article	IF	Citations
19	Reduction in Nonabstinent <scp>WHO</scp> Drinking Risk Levels and Change in Risk for Liver Disease and Positive <scp>AUDIT</scp>â€C Scores: Prospective 3â€Year Followâ€Up Results in the <scp>U.S.</scp> General Population. Alcoholism: Clinical and Experimental Research, 2018, 42, 2256-2265.	2.4	43
20	Reduction in non-abstinent WHO drinking risk levels and depression/anxiety disorders: 3-year follow-up results in the US general population. Drug and Alcohol Dependence, 2019, 197, 228-235.	3.2	42
21	A Doubleâ€Blind, Placeboâ€Controlled Trial Assessing the Efficacy of Levetiracetam Extendedâ€Release in Very Heavy Drinking Alcoholâ€Dependent Patients. Alcoholism: Clinical and Experimental Research, 2012, 36, 1421-1430.	2.4	41
22	Maintenance of World Health Organization Risk Drinking Level Reductions and Posttreatment Functioning Following a Large Alcohol Use Disorder Clinical Trial. Alcoholism: Clinical and Experimental Research, 2019, 43, 979-987.	2.4	41
23	The Alcohol Clinical Trials Initiative (ACTIVE): Purpose and Goals for Assessing Important and Salient Issues for Medications Development in Alcohol Use Disorders. Neuropsychopharmacology, 2012, 37, 402-411.	5.4	25
24	Five-Year Healthcare Utilization and Costs Among Lower-Risk Drinkers Following Alcohol Treatment. Alcoholism: Clinical and Experimental Research, 2014, 38, 579-586.	2.4	25
25	Missing Data in Alcohol Clinical Trials with Binary Outcomes. Alcoholism: Clinical and Experimental Research, 2016, 40, 1548-1557.	2.4	25
26	Temporal Stability of Heavy Drinking Days and Drinking Reductions Among Heavy Drinkers in the <scp>COMBINE</scp> Study. Alcoholism: Clinical and Experimental Research, 2017, 41, 1054-1062.	2.4	25
27	Posttreatment Low-Risk Drinking as a Predictor of Future Drinking and Problem Outcomes Among Individuals with Alcohol Use Disorders: A 9-Year Follow-Up. Alcoholism: Clinical and Experimental Research, 2017, 41, 653-658.	2.4	24
28	Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatmentâ€Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Doubleâ€Blind, Placeboâ€Controlled Clinical Trial of Varenicline. Alcoholism: Clinical and Experimental Research, 2020, 44, 1431-1443.	2.4	23
29	Reduction in non-abstinent World Health Organization (WHO) drinking risk levels and drug use disorders: 3-year follow-up results in the US general population. Drug and Alcohol Dependence, 2019, 201, 16-22.	3.2	19
30	Medication Development for Alcohol Use Disorder: A Focus on Clinical Studies. Handbook of Experimental Pharmacology, 2019, 258, 443-462.	1.8	19
31	Five Priority Areas for Improving Medications Development for Alcohol Use Disorder and Promoting Their Routine Use in Clinical Practice. Alcoholism: Clinical and Experimental Research, 2020, 44, 23-35.	2.4	17
32	Research Opportunities for Medications to Treat Alcohol Dependence: Addressing Stakeholders' Needs. Alcoholism: Clinical and Experimental Research, 2014, 38, 27-32.	2.4	14
33	An exploratory evaluation of Take Control : A novel computer-delivered behavioral platform for placebo-controlled pharmacotherapy trials for alcohol use disorder. Contemporary Clinical Trials, 2016, 50, 178-185.	1.8	13
34	Cumulative Proportion of Responders Analysis (CPRA) as a Tool to Assess Treatment Outcome in Alcohol Clinical Trials. Journal of Studies on Alcohol and Drugs, 2014, 75, 335-346.	1.0	11
35	Alcohol Medications Development: Advantages and Caveats of Government/Academia Collaborating with the Pharmaceutical Industry. Alcoholism: Clinical and Experimental Research, 2014, 38, 1196-1199.	2.4	9
36	Letter to Editor in Response to Johnson's Commentary (2017) on the Witkiewitz and Colleagues (2017) Article. Alcoholism: Clinical and Experimental Research, 2017, 41, 1381-1382.	2.4	5

#	Article	IF	Citations
37	Response to Dr. Mark Litt's Commentary. Alcoholism: Clinical and Experimental Research, 2019, 43, 2255-2256.	2.4	0